116 CHAPTER 4 Supplementary Table 2 and Supplementary Table 3 will be made available online upon publication of the article. • Supplementary Table 2: All identified and quantified phosphosites • Supplementary Table 3: All identified and quantified phosphopeptides and proteins Supplementary Table 4. Role of proteins corresponding to candidate phosphosite signature (n = 78) in RCC a: phosphosites upregulated in primary resistant patients Phosphosite p-value FC Role of corresponding protein in RCC Uniquely identified in resistant tumors BCAR3_Y117 n/a n/a No literature describing a role in RCC. EIF4A2_Y251 n/a n/a NOP58_Y272 n/a n/a GDI1_Y93 n/a n/a Differentially upregulated (not unique) ZNF618_T647 0.004 22.2 No literature describing a role in RCC. CD247_Y141 0.008 15.2 A relatively high expression of CD247, which represents a target for immunotherapy, is found in ccRCC compared to normal tissue82,83 MYOF_Y416 0.009 22.0 MYOF influences cellular proliferation of the metastatic CCRCC cell line by regulating VEGFR2 degradation84 and MYOF hyperexpression was significantly associated with disease-free survival85. CD247_Y110 0.013 12.2 A relatively high expression of CD247, which represents a target for immunotherapy, is found in ccRCC compared to normal tissue82,83. APBB1IP_Y380 0.018 2.8 No literature describing a role in RCC. PTTG1IP_Y144 0.018 3.1 No literature describing a role in RCC. ATP5PD_Y126 0.020 7.3 ATP5PD is differentially expressed between ccRCC tissue en normal renal tissue86. NCS1_Y97 0.022 9.4 No literature describing a role in RCC. DOK3_Y342 0.023 6.3 In an in vitro study, DOK3 was downregulated in RCC cell lines after stimulation with insulin and insulin-like growth factors (IGFs), stimulating RCC tumorigenesis and progression87. CLDN1_Y210 0.025 6.0 CLDN1 is expressed in RCC cells in a PAX8dependent manner88. STAT4_Y693 0.029 4.2 No literature describing a role in RCC.
RkJQdWJsaXNoZXIy MTk4NDMw